The Research
Opioids used in pregnancy can be associated with additional risks to both mother and fetus. Opioid treatment during pregnancy has been found to be associated with birth defects (Yazdy, et al, 2013; Broussard, et al, 2011) ), preterm delivery, poor fetal growth, stillbirth (Whiteman et al, 2014) , and neonatal opioid withdrawal syndrome (Hadi, et al, 2006) . Neonatal Abstinence Syndrome (NAS)
Current Legislation
One major piece of legislation that has been amended over the years is the Reauthorization of the Child Abuse and Prevention Treatment Act (CAPTA, 2010). The Act requires statewide policies and procedures to address the needs of infants affected by illegal substance abuse or a Fetal Alcohol Spectrum.
On November 25, 2015, President Obama signed Protecting Our Infants Act of 2015 into law. Because prevention and treatment efforts vary widely from state to state, the new law will help identify evidence-based approaches to care for these babies and their mothers. The law requires the Department of Health and Human Services to conduct a study and develop recommendations for preventing and treating prenatal opioid use disorders and NAS. In addition, the Centers for Disease Control and Prevention will continue to assist states in improving the availability and quality of data collection related to NAS, and encourage public health measures aimed at decreasing its prevalence. • Surveillance for NAS-affected infants and the sources of maternal opiate use.
• Reimbursement for utilizing screening protocols to detect substance abuse early in pregnancy and withdrawal signs in newborns.
• Development of better measures to ensure follow-up with opioid-dependent women and receipt of comprehensive services.
• Collaborative efforts to strengthen clinical standards for identification, management, and follow-up with NAS-affected infants and their families.
